Century Therapeutics Inc. (Ticker: IPSC) is a pioneering biotechnology company specializing in allogenic cell therapies designed to revolutionize cancer treatment. Leveraging its proprietary induced pluripotent stem cell (iPSC) technology, the firm is dedicated to creating innovative off-the-shelf therapeutic solutions that improve patient outcomes and expand accessibility. With a diverse pipeline of clinical-stage candidates and key strategic alliances that enhance its market position, Century Therapeutics is well-positioned to drive significant advancements in the cell therapy landscape, presenting promising opportunities for clinical achievement and solid returns for investors.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-86.19M |
| EBITDA | $-101.60M |
| Operating Margin | 0.00% |
| Return on Equity | -42.70% |
| Return on Assets | -22.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.82 |
| Price-to-Book | 1.55 |
| Price-to-Sales (TTM) | 3.72 |
| EV/Revenue | 3.126 |
| EV/EBITDA | 131.51 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $180.35M |
| Float | $97.85M |
| % Insiders | 12.07% |
| % Institutions | 76.86% |
Volatility is currently contracting